Nonetheless, to date the only FDA- and EMA-approved NRF2 activator for the treatment of relapsing-remitting MS and psoriasis is DMF, and its therapeutic potential in ALS patients in terms of efficacy, safety and tolerability, is now being evaluated in a phase-II clinical trial [313]
It far outperforms the pill form
As the primary barrier to environmental and metabolic stress, the skin is susceptible to oxidative damage
Aggressive Short-Term Protocols For acute injuries where rapid recovery matters, some users employ higher initial doses before settling into maintenance ranges
Usage Subcutaneous injection once weekly
Manufactured exclusively for research applications, BPC-157 is intended for qualified laboratory professionals conducting non-clinical studies